Grant Detail
This is a chronological listing of grants held by this department, with the most recent listed first. New grants appear in this list weekly and contribute related to the department's Research Profile. The source of grants for this application comes directly from your institution.
OMB110927 A Single Arm, Safety and Efficacy Study of Ofatumumab in Combinatio
Thomas Shea
2/26/2009 - 2/25/2012| Sponsoring Organization: | Industry Sponsor |
| Awarding Organization Is: | University of North Carolina at Chapel Hill |
| Funding: | $ 1,674.00 |
Thomas C Shea (Lead Principal Investigator)
The primary objective is to evaluate the overall response rate of ofatumumab in combination with ICE or DHAP chemotherapy prior to autologous stem cell transplant. Secondary objectives are to evaluate the CR rate, ability to mobilize CD34+ cells, safety, tolerability, B symptoms, ofatumumab pharmacokinetics (PK), progression-free and overall survival in subjects treated with ofatumumab in combination with either ICE or DHAP.
